🟢 Cue Biopharma is trading 5.17% up in pre-market; no verified company-specific catalyst identified

Cue Biopharma is trading 5.17% up in pre-market at $29.70, with no new verified company-specific announcement identified to explain the move.

• It rose 8.20% during the August 11 regular session.
• The latest official release concerns CFO James M. Ahlers’ appointment and the CUE-221 investigational new drug submission, announced August 3 and updated August 11.
• The move may reflect continued momentum and a modestly positive pre-market backdrop; an earnings date around August 11–19 remains unconfirmed.